Security Snapshot

Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) Institutional Ownership

CUSIP: 98937L105

13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

117

Shares (Excl. Options)

41,561,364

Price

$36.31

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
ZBIO on Nasdaq
Shares outstanding
63,202,357
Price per share
$19.55
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
41,561,364
Total reported value
$1,504,857,228
% of total 13F portfolios
0.01%
Share change
+6,453,549
Value change
+$255,199,514
Number of holders
117
Price from insider filings
$19.55
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 98937L105.
  • 117 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 117 to 2 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,504,857,228 to $12,024.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 98937L105?
CUSIP 98937L105 identifies ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 14% +30% $277,876,336 +$109,228,632 7,652,255 +65% FMR LLC 31 Dec 2025
SR ONE CAPITAL MANAGEMENT, LLC 9.4% $111,851,442 5,037,854 SR One Capital Management, LLC 09 Oct 2025
InnoCare Pharma Inc. 9.4% $111,026,500 5,000,000 InnoCare Pharma Inc. 07 Oct 2025
Enavate Sciences GP, LLC 7.3% $87,013,952 3,919,159 Enavate Sciences GP, LLC 09 Oct 2025
MOULDER LEON O JR 4.8% -7.4% $76,596,403 +$5,640,701 3,029,921 +7.9% Leon O. Moulder, Jr. 31 Mar 2026
Longitude Capital Partners IV, LLC 4.9% $58,425,578 2,631,522 Patrick G. Enright 09 Oct 2025
Novo Holdings A/S 4.7% -12% $44,400,000 -$4,772,267 2,000,000 -9.7% Novo Holdings A/S 30 Sep 2025

As of 31 Dec 2025, 117 institutional investors reported holding 41,561,364 shares of Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO). This represents 66% of the company’s total 63,202,357 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 12% 7,704,255 +60% 0.01% $279,741,500
SR One Capital Management, LP 8% 5,037,854 +2.6% 26% $182,924,479
ENAVATE SCIENCES GP, LLC 6.2% 3,919,159 +4.2% 28% $142,304,663
NEA Management Company, LLC 5.6% 3,523,219 +29% 6.5% $127,928,082
FEDERATED HERMES, INC. 4.3% 2,715,578 +46% 0.16% $98,602,637
Fairmount Funds Management LLC 3.5% 2,209,025 +17% 6.1% $80,209,698
NVP ASSOCIATES, LLC 2.9% 1,838,482 0% 26% $66,755,281
BlackRock, Inc. 2.8% 1,767,518 +44% 0% $64,178,579
VANGUARD GROUP INC 2.3% 1,453,065 +25% 0% $52,760,791
NOVO HOLDINGS A/S 2.3% 1,450,000 -28% 4.1% $52,649,500
Polar Capital Holdings Plc 1.7% 1,057,609 0.18% $38,401,783
WELLINGTON MANAGEMENT GROUP LLP 1.4% 855,334 -0.26% 0.01% $31,057,177
Vivo Capital, LLC 1.4% 853,495 -28% 2% $30,990,403
EcoR1 Capital, LLC 1.2% 789,500 1.3% $28,666,745
ArrowMark Colorado Holdings LLC 1.2% 751,161 -8.9% 0.6% $27,274,656
Pivotal bioVenture Partners Investment Advisor LLC 0.94% 591,991 -24% 8.3% $21,495,193
GEODE CAPITAL MANAGEMENT, LLC 0.93% 588,393 +25% 0% $21,370,527
Rock Springs Capital Management LP 0.79% 502,077 -14% 0.94% $18,230,416
STATE STREET CORP 0.69% 438,294 +16% 0% $15,914,455
PRICE T ROWE ASSOCIATES INC /MD/ 0.58% 369,248 -1.3% 0% $13,408,000
Point72 Asset Management, L.P. 0.58% 368,400 0.01% $9,213,684
NEXTBio Capital Management LP 0.51% 321,983 0% 6.9% $11,691,203
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.34% 213,193 +20% 0% $7,741,038
Balyasny Asset Management L.P. 0.31% 193,153 0.01% $7,013,385
Invesco Ltd. 0.3% 187,968 +29% 0% $6,825,118

Institutional Holders of Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 615 $12,024 -$2,204 $19.55 2
2025 Q4 41,561,364 $1,504,857,228 +$255,199,514 $36.31 117
2025 Q3 34,774,383 $771,813,059 +$23,276,708 $22.20 78
2025 Q2 34,055,191 $329,977,952 +$15,611,752 $9.69 72
2025 Q1 32,489,801 $256,715,238 +$5,759,402 $7.90 67
2024 Q4 31,699,756 $259,632,936 +$20,083,837 $8.19 65
2024 Q3 24,771,152 $418,526,187 +$418,475,122 $16.92 44

Sponsored